Calliditas Therapeutics AB American Depositary Shares
CALT
CALT was delisted on the 20th of September, 2024.
16 hedge funds and large institutions have $13.9M invested in Calliditas Therapeutics AB American Depositary Shares in 2023 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 6 increasing their positions, 2 reducing their positions, and 2 closing their positions.
200% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 2
100% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 2
14% more funds holding
Funds holding: 14 → 16 (+2)
11% less call options, than puts
Call options by funds: $89K | Put options by funds: $100K
34% less capital invested
Capital invested by funds: $21M → $13.9M (-$7.16M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$26.8K |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$24.3K |
| 3 |
Simplex Trading
Chicago,
Illinois
|
+$24K |
| 4 |
Osaic Holdings
Scottsdale,
Arizona
|
+$21.2K |
| 5 |
FDCDDQ
Federation des caisses Desjardins du Quebec
Levis,
Quebec, Canada
|
+$10.6K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Group One Trading
Chicago,
Illinois
|
-$16.9K |
| 2 |
IIM
Ironwood Investment Management
Boston,
Massachusetts
|
-$12.3K |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$2.72K |
| 4 |
BAM
Belpointe Asset Management
Reno,
Nevada
|
-$2.42K |
CALT Hedge Fund Activity: Q2 2023 in Review
16 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Calliditas Therapeutics AB American Depositary Shares (CALT) for Q2 2023, worth a combined $13.9M — down 34% from $21M a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new CALT positions and 2 closed out — a net gain of 2 holders — while 6 added to existing stakes and 2 trimmed.
The largest buyer was Morgan Stanley, adding an estimated $26.8K. The largest seller was Group One Trading, exiting entirely with an estimated $16.9K sold.
- 16 institutional investors held Calliditas Therapeutics AB American Depositary Shares (CALT) as of Q2 2023, up from 14 in Q1 2023.
- Funds reported $13.9M of Calliditas Therapeutics AB American Depositary Shares stock for Q2 2023, down 34% quarter-over-quarter.
- 4 funds opened new Calliditas Therapeutics AB American Depositary Shares positions in Q2 2023 and 2 closed out, a net change of +2 holders.
- The largest Calliditas Therapeutics AB American Depositary Shares buyer in Q2 2023 was Morgan Stanley, an estimated $26.8K added.
- The largest Calliditas Therapeutics AB American Depositary Shares seller in Q2 2023 was Group One Trading, an estimated $16.9K sold.
Based on aggregated 13F filings for Q2 2023.